Apolipoprotein profiles in subjects with and without peripheral artery disease

Andrew W. Gardner, Petar Alaupovic, Donald E. Parker, Polly S. Montgomery, Ashley Roof, Ana I. Casanegra

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

We compared plasma apolipoprotein profiles in subjects with peripheral artery disease (PAD) treated with statin medications (n = 21), subjects with PAD who are untreated with statins (n = 18), and control subjects (n = 70). Subjects were assessed on plasma apolipoproteins, medical history, physical examination, ankle-brachial index, and exercise performance using a treadmill test. The percentage of subjects with an abnormal value of apolipoprotein B (ApoB) (≥ 95 mg/dL) was 53% in the PAD group untreated with statins, 29% in the treated PAD group, and 13% in the controls (p < 0.001). The PAD group untreated with statins had higher values for ApoB (p < 0.001), triglycerides (p < 0.01), low-density lipoprotein (LDL)-cholesterol / high-density lipoprotein (HDL)-cholesterol ratio (p < 0.05), and glucose (p < 0.01) than the control group. In contrast, when the statin-treated PAD group was compared with controls, none of the variables were different except that the treated PAD group had lower LDL-cholesterol (p < 0.01) and higher glucose (p < 0.01). Furthermore, the PAD group treated with statins had lower ApoB (p < 0.01), triglycerides (p < 0.001), LDL-cholesterol (p < 0.05), LDL-cholesterol / HDL-cholesterol ratio (p < 0.05), and non-HDL-cholesterol (p < 0.05) than the untreated PAD group. In conclusion, subjects with PAD who are untreated with statin medications have higher levels of ApoB than controls, whereas subjects treated with statins have a more favorable risk profile, characterized by lower ApoB, LDL-C, LDL-C / HDL-C ratio, and non-HDL-C concentrations. Statin therapy may be efficacious for improving apolipoprotein profiles in subjects with PAD and intermittent claudication.

Original languageEnglish (US)
Pages (from-to)129-135
Number of pages7
JournalVascular Medicine (United Kingdom)
Volume18
Issue number3
DOIs
StatePublished - Jun 2013

Fingerprint

Apolipoproteins
Peripheral Arterial Disease
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Apolipoproteins B
Triglycerides
LDL Cholesterol
LDL Lipoproteins
HDL Cholesterol
Glucose
Ankle Brachial Index
Intermittent Claudication
HDL Lipoproteins
Exercise Test
Lipoproteins
Physical Examination

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Gardner, Andrew W. ; Alaupovic, Petar ; Parker, Donald E. ; Montgomery, Polly S. ; Roof, Ashley ; Casanegra, Ana I. / Apolipoprotein profiles in subjects with and without peripheral artery disease. In: Vascular Medicine (United Kingdom). 2013 ; Vol. 18, No. 3. pp. 129-135.
@article{c1dcb548720645ac9ab7139497cc5770,
title = "Apolipoprotein profiles in subjects with and without peripheral artery disease",
abstract = "We compared plasma apolipoprotein profiles in subjects with peripheral artery disease (PAD) treated with statin medications (n = 21), subjects with PAD who are untreated with statins (n = 18), and control subjects (n = 70). Subjects were assessed on plasma apolipoproteins, medical history, physical examination, ankle-brachial index, and exercise performance using a treadmill test. The percentage of subjects with an abnormal value of apolipoprotein B (ApoB) (≥ 95 mg/dL) was 53{\%} in the PAD group untreated with statins, 29{\%} in the treated PAD group, and 13{\%} in the controls (p < 0.001). The PAD group untreated with statins had higher values for ApoB (p < 0.001), triglycerides (p < 0.01), low-density lipoprotein (LDL)-cholesterol / high-density lipoprotein (HDL)-cholesterol ratio (p < 0.05), and glucose (p < 0.01) than the control group. In contrast, when the statin-treated PAD group was compared with controls, none of the variables were different except that the treated PAD group had lower LDL-cholesterol (p < 0.01) and higher glucose (p < 0.01). Furthermore, the PAD group treated with statins had lower ApoB (p < 0.01), triglycerides (p < 0.001), LDL-cholesterol (p < 0.05), LDL-cholesterol / HDL-cholesterol ratio (p < 0.05), and non-HDL-cholesterol (p < 0.05) than the untreated PAD group. In conclusion, subjects with PAD who are untreated with statin medications have higher levels of ApoB than controls, whereas subjects treated with statins have a more favorable risk profile, characterized by lower ApoB, LDL-C, LDL-C / HDL-C ratio, and non-HDL-C concentrations. Statin therapy may be efficacious for improving apolipoprotein profiles in subjects with PAD and intermittent claudication.",
author = "Gardner, {Andrew W.} and Petar Alaupovic and Parker, {Donald E.} and Montgomery, {Polly S.} and Ashley Roof and Casanegra, {Ana I.}",
year = "2013",
month = "6",
doi = "10.1177/1358863X13489768",
language = "English (US)",
volume = "18",
pages = "129--135",
journal = "Vascular Medicine",
issn = "1358-863X",
publisher = "SAGE Publications Ltd",
number = "3",

}

Gardner, AW, Alaupovic, P, Parker, DE, Montgomery, PS, Roof, A & Casanegra, AI 2013, 'Apolipoprotein profiles in subjects with and without peripheral artery disease', Vascular Medicine (United Kingdom), vol. 18, no. 3, pp. 129-135. https://doi.org/10.1177/1358863X13489768

Apolipoprotein profiles in subjects with and without peripheral artery disease. / Gardner, Andrew W.; Alaupovic, Petar; Parker, Donald E.; Montgomery, Polly S.; Roof, Ashley; Casanegra, Ana I.

In: Vascular Medicine (United Kingdom), Vol. 18, No. 3, 06.2013, p. 129-135.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Apolipoprotein profiles in subjects with and without peripheral artery disease

AU - Gardner, Andrew W.

AU - Alaupovic, Petar

AU - Parker, Donald E.

AU - Montgomery, Polly S.

AU - Roof, Ashley

AU - Casanegra, Ana I.

PY - 2013/6

Y1 - 2013/6

N2 - We compared plasma apolipoprotein profiles in subjects with peripheral artery disease (PAD) treated with statin medications (n = 21), subjects with PAD who are untreated with statins (n = 18), and control subjects (n = 70). Subjects were assessed on plasma apolipoproteins, medical history, physical examination, ankle-brachial index, and exercise performance using a treadmill test. The percentage of subjects with an abnormal value of apolipoprotein B (ApoB) (≥ 95 mg/dL) was 53% in the PAD group untreated with statins, 29% in the treated PAD group, and 13% in the controls (p < 0.001). The PAD group untreated with statins had higher values for ApoB (p < 0.001), triglycerides (p < 0.01), low-density lipoprotein (LDL)-cholesterol / high-density lipoprotein (HDL)-cholesterol ratio (p < 0.05), and glucose (p < 0.01) than the control group. In contrast, when the statin-treated PAD group was compared with controls, none of the variables were different except that the treated PAD group had lower LDL-cholesterol (p < 0.01) and higher glucose (p < 0.01). Furthermore, the PAD group treated with statins had lower ApoB (p < 0.01), triglycerides (p < 0.001), LDL-cholesterol (p < 0.05), LDL-cholesterol / HDL-cholesterol ratio (p < 0.05), and non-HDL-cholesterol (p < 0.05) than the untreated PAD group. In conclusion, subjects with PAD who are untreated with statin medications have higher levels of ApoB than controls, whereas subjects treated with statins have a more favorable risk profile, characterized by lower ApoB, LDL-C, LDL-C / HDL-C ratio, and non-HDL-C concentrations. Statin therapy may be efficacious for improving apolipoprotein profiles in subjects with PAD and intermittent claudication.

AB - We compared plasma apolipoprotein profiles in subjects with peripheral artery disease (PAD) treated with statin medications (n = 21), subjects with PAD who are untreated with statins (n = 18), and control subjects (n = 70). Subjects were assessed on plasma apolipoproteins, medical history, physical examination, ankle-brachial index, and exercise performance using a treadmill test. The percentage of subjects with an abnormal value of apolipoprotein B (ApoB) (≥ 95 mg/dL) was 53% in the PAD group untreated with statins, 29% in the treated PAD group, and 13% in the controls (p < 0.001). The PAD group untreated with statins had higher values for ApoB (p < 0.001), triglycerides (p < 0.01), low-density lipoprotein (LDL)-cholesterol / high-density lipoprotein (HDL)-cholesterol ratio (p < 0.05), and glucose (p < 0.01) than the control group. In contrast, when the statin-treated PAD group was compared with controls, none of the variables were different except that the treated PAD group had lower LDL-cholesterol (p < 0.01) and higher glucose (p < 0.01). Furthermore, the PAD group treated with statins had lower ApoB (p < 0.01), triglycerides (p < 0.001), LDL-cholesterol (p < 0.05), LDL-cholesterol / HDL-cholesterol ratio (p < 0.05), and non-HDL-cholesterol (p < 0.05) than the untreated PAD group. In conclusion, subjects with PAD who are untreated with statin medications have higher levels of ApoB than controls, whereas subjects treated with statins have a more favorable risk profile, characterized by lower ApoB, LDL-C, LDL-C / HDL-C ratio, and non-HDL-C concentrations. Statin therapy may be efficacious for improving apolipoprotein profiles in subjects with PAD and intermittent claudication.

UR - http://www.scopus.com/inward/record.url?scp=84878375211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878375211&partnerID=8YFLogxK

U2 - 10.1177/1358863X13489768

DO - 10.1177/1358863X13489768

M3 - Article

C2 - 23720036

AN - SCOPUS:84878375211

VL - 18

SP - 129

EP - 135

JO - Vascular Medicine

JF - Vascular Medicine

SN - 1358-863X

IS - 3

ER -